Commentary on the "Evidence- and Consensus-Based (S3) Guidelines for the Treatment of Actinic Keratosis" Published by the International League of Dermatological Societies in Cooperation with the European Dermatology Forum.
Skin Pharmacol Physiol
; 31(3): 144-146, 2018.
Article
en En
| MEDLINE
| ID: mdl-29614495
ABSTRACT
In 2015, the International League of Dermatological Societies and the European Dermatology Forum published a guideline for the treatment of actinic keratosis, which is classified as an evidence- and consensus-based S3 guideline. From the point of view of the GD Task Force "Licht.Hautkrebs.Prävention," an interdisciplinary expert panel of the Society for Dermopharmacy for the prevention and treatment of skin cancer, this guideline reveals strengths and weaknesses but, in summary, does not meet the claim for an evidence- and consensus-based S3 guideline.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Guías de Práctica Clínica como Asunto
/
Queratosis Actínica
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Skin Pharmacol Physiol
Asunto de la revista:
DERMATOLOGIA
/
FARMACOLOGIA
/
FISIOLOGIA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Alemania